anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 236,551-236,580
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

236,551-236,580 of 303,780

filter-aware
21
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
23
The slide explicitly mentions a 'flywheel' model, though it is presented as a data visualization rather than a process diagram.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
24
The left chart is a combo chart (bar + line). The right chart is a bar chart comparing Freightos to 6 other companies.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
25
The left chart uses a 'Path to Profitability' arrow to visually emphasize the trend.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
26
Includes a note regarding the acquisition of Shipsta.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
28
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
29
This is a closing slide for an investor presentation.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Loop · Golden Circle1 hit
30
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Loop · Golden Circle1 hit
32
The table includes a footnote regarding non-recurring share listing expenses.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
33
The table shows adjustments for share-based compensation and depreciation & amortization to arrive at non-IFRS metrics.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
34
The table provides a clear breakdown of non-cash and non-recurring items used to adjust the operating loss.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
35
The table shows a significant increase in operating loss in 2023, largely driven by share-listing expenses.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
36
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
37
The table details non-cash and non-recurring items to arrive at Adjusted EBITDA.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
38
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
01
Slide 1
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
02
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
03
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
04
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
05
The slide uses a Gantt-style visualization to show the progress of various drug candidates through clinical phases.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Need1 hit
08
Uses a 'brake pedal' analogy to explain biological function.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
10
The process is presented as a sequential workflow.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
12
The slide uses a numbered list format to explain the mechanism of action.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
14
The slide uses a series of circles to present key metrics, highlighting the global market size as the central focus.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
15
ONC-001 TrialGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
18
The slide uses a 'problem-solution' framing, highlighting the limitation of existing drugs and the mechanism of the company's therapy.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
19
The slide includes a timeline of the study and two line charts showing tumor volume over time for different treatment groups.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
20
The slide outlines a multi-phase clinical trial structure (Phase 1, 2a, 2b) and provides specific patient counts and interim analysis milestones.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
23
The table highlights a statistically significant difference (p=0.0008) in TUSC2 protein expression between SCLC and NSCLC.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
25
Kaplan-Meier survival curve showing PFS. Mentions Tecentriq as brand name for Atezolizumab.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit